Summary A subline (COR-L23/R) of the human large cell lung cancer line COR-L23, derived by in vivo exposure to doxorubicin, exhibits an unusual multidrug resistant (MDR) phenotype. This subline shows cross-resistance to daunorubicin, vincristine, colchicine and etoposide but does not express P-glycoprotein. Interestingly, COR-L12/R shows little or no resistance to a range of structurally-modified analogues of doxorubicin comprising 9-alkyl and/or sugar modified anthracyclines. We have previously identified these same compounds as effective agents against P-glycoprotein-positive MDR cell lines. In contrast to typical MDR cell lines, COR-L12/R shows only minimal chemosensitisation by verapamil and no collateral sensitivity to verapamil. Compared to the parental cell line, COR-L12/R displays reduced accumulation of doxorubicin and daunorubicin. Accumulation defects were apparent only after 0.5-1 h of incubation of cells with these agents. The rate of daunorubicin efflux was shown to be enhanced by COR-L12/R and this efflux was demonstrated to be energy-dependent. The use of anthracyclines which retain activity in MDR cells thus appears to be a valid approach for the circumvention of MDR, not only in cells which express P-glycoprotein, but also where defective drug accumulation is due to other mechanisms possibly involving an alternative multidrug transporter.
The hyperexpression of membrane P-glycoprotein is now a well established correlate of multidrug resistance (MDR) in cultured cancer cell lines (Juliano & Ling, 1976; Kartner et al., 1983; Endicott & Ling, 1989) . There are, however, a number of reports describing cell lines which exhibit crossresistance to the usual range of amphipathic high molecular weight natural products normally associated with MDR, but which do not show P-glycoprotein hyperexpression. For example, the presence of P-glycoprotein could not be detected in an HL-60 human leukaemia cell line with in vitro acquired resistance to doxorubicin (Marsh & Center, 1987) . However, a phosphorylated protein designated P-1 50 was isolated from membrane preparations of the drug resistant but not the drug sensitive variant (Marsh & Center, 1987) . Similarly an MDR variant of the human small cell lung cancer line NCI-H69 was derived by in vitro by exposure to doxorubicin and likewise did not express P-glycoprotein (Mirski et al., 1987) . This latter report contrasts strikingly with the observation in our laboratory that in a different MDR variant of the NCI-H69 cell line, also derived by in vitro exposure to doxorubicin, there is clear membrane Pglycoprotein hyperexpression as well as mdr gene amplification (Reeve et al., 1989a) . Whereas it has become accepted that P-glycoprotein acts as a drug efflux pump and that defective drug accumulation is usually associated with its hyperexpression (Endicott & Ling, 1989; Fojo et al., 1985; Kessel & Corbett, 1985) , the mechanistic basis for MDR in the absence of P-glycoprotein remains to be elucidated.
Two therapeutic approaches have been taken to the problem of MDR in the hope of eventual application in a clinical setting. One has been the use of 'resistance modifiers' such as verapamil which at least partially restore sensitivity in MDR cells to the agents to which they have become resistant (Tsuruo et al., 1983 (Tsuruo et al., , 1984 Ramu et al., 1984; Kessel & Wilberding, 1985; Kessel, 1985) . The other approach involves the identification of analogues of MDR-associated drugs which retain activity in resistant cells, most probably because they are not effluxed as efficiently by P-glycoprotein (Twentyman et al., 1986a; Scott et al., 1986; Coley et al., 1989a) . In previous studies we have shown with our P-glycoproteinpositive cell lines that these include anthracyclines having either a 9-alkyl substitution in the A-ring or sugar modifications such as replacement of the amino group of the daunosamine moiety with a morpholinyl ring (Scott et al., 1986; Coley et al., 1989a) . There may be a particular advantage for combining both moieties within the same molecules, as in the analogue MX2 (Coley et al., 1990) . We were further able to demonstrate a cellular pharmacokinetic basis for such differential retention of activity and also for the action of resistance modifiers verapamil and cyclosporin A (Coley et al., 1989b) .
Recent reports from this laboratory (Twentyman et al., 1989b; Reeve et al., 1990) have described an MDR variant of the human large cell lung cancer cell line COR-L23 (BaillieJohnson et al., 1985) . This variant, COR-L23/R, was derived by in vitro exposure to doxorubicin and shows cross-resistance to vincristine and colchicine. However, it does not hyperexpress the mdr I gene as determined by Northern blotting or its product, P-glycoprotein, as determined by Western blotting or immunocytochemistry with antibody C219 (Kartner et al., 1985) . It does, however, show reduced expression of the EGF receptor (Reeve et al., 1990) . We now report on the sensitivity of COR-L23/R to 'low-resistance anthracyclines', the degree of resistance modification by verapamil, and the differences in cellular pharmacokinetics between the resistant and parent lines. A preliminary report of these studies has appeared in abstract form (Coley et al., 1989c) .
Materials and methods
Cell lines and culture conditions The human large cell lung cancer parental cell line COR-L23/P was derived in this laboratory (Baille-Johnson et al., 1985) and doxorubicin-resistant variant COR-L23/R was developed from it by continuous step-wise in vitro incubation with increasing concentrations of doxorubicin (Twentyman et al., 1986b) . COR-L23/R was maintained in culture in the presence of 0.2 jig ml-' doxorubicin. Parental and drug resistant cell lines were grown as monolayer cultures in RPMI medium (Gibco, Paisley, UK) with 10% foetal calf serum (Seralab, Crawley Down, UK), penicillin and streptomycin (at concentrations 100 units ml' and 100 g ml1 ', respectively Cytotoxic drugs were dissolved directly in sterile distilled water at 500 Lg ml-l in the case of doxorubicin, daunorubicin, Ro 31-1215, aclarubicin, iodo-doxorubicin, morpholinyl doxorubicin and MX2 and sterilised by membrane filtration. Colchicine was similarly prepared by at 200 ILg ml1'. Verapamil was obtained as a 2 mg ml1' aqueous solution in sealed ampoules and diluted in PBS immediately prior to use. Vincristine was obtained as a sterile lyophilised plug and reconstituted with sterile distilled water to give a stock solution of 500 tg ml-'. Etoposide was obtained as a solution of concentration 20 mg ml-' in an ethanol-based solvent, in sealed ampoules. This was diluted in sterile distilled water to give a final working solution of 500 g ml-.
Chemosensitivity testing using the MTT assay This was carried out as previously described (Coley et al., 1989a; Twentyman & Luscombe, 1987) . Briefly, cell suspensions were dispensed in 200 ,l aliquots into 96 well tissue culture plates (Falcon Plastics, Cowley, UK) to give 1 x 103 and 2 x I03cells/well for COR-L23/P and COR-L23/R respectively. The plates were then incubated for 2-3 h at 37°C to allow medium equilibration and cell attachment. Drugs were then added to the wells in a volume of 20 ll to produce the final concentration required. The range selected encompassed drug doses estimated to produce a decrease in final optical density to less than 10% of that given by the control, drug-free cells. Cells were exposed continuously following a single drug administration for a 6 day period at 37°C during which time there was a 10-20-fold increase in cell number for untreated control cells. MTT solution (5 mg ml-' in PBS, Sigma, Poole, UK) was then added to each well in a volume of 20 ILI and the plates incubated for 5 h at 37°C. The medium was then aspirated from the wells and 200 LIl of DMSO (BDH, Poole, UK) was added to dissolve the crystalline formazan reaction product. The plates were agitated for 10 min and absorbances were read on a Titertek Multiskan MCC ELISA plate reader (Flow Laboratories, Rickmansworth, UK) at a measuring wavelength of 540 nm and a reference wavelength of 690 nm. Absorbance values obtained were expressed as a fraction of those obtained for control wells. In all experiments 3-6 replicate wells were used for each drug concentration.
Effects of verapamil on chemosensitisation
Verapamil was added to wells in a volume of 10 Il, 2-3 h after cell inoculation to give a final concentration of 3.3 lAg ml-' (6.6 pLM). The plates were incubated at 37°C for a further 2-3 h before the addition of the cytotoxic agents. For determination of the sensitivity to verapamil alone, however, the drug was added in a total volume of 20 lI. The MTT assay was then performed as above.
Cellular pharmacokinetics
Anthracycline accumulation The method used to determine the anthracycline content per cell was essentially that of Schwartz (1973) . Doxorubicin and aclarubicin were used at working concentrations of 10 1g ml-' and iodo-doxorubicin and Ro 31-1215 at 1 pg ml-' (according to the intrinsic fluorescence of the individual compounds). Cell suspensions (106 cells in 5 ml) were brought to 37°C and drug solutions were added in 100 tl volumes. During the incubation period, the tubes were agitated at 10 min intervals.
At the appropriate time points the tubes were centrifuged rapidly at 4°C (300 g for 2 min) and the cells washed twice in ice-cold PBS. A volume of 0.2 ml of ice-cold silver nitrate solution (33% w/v) was then added followed by a further 10 min shaking period and centrifugation for 5 min at 200g. At the end of this time period, 4 ml of iso-amyl alcohol was added followed by a further 10 min shaking period and centrifugation for 5 min at 200 g. The alcohol layer was then transferred to a 4 ml boro-silicate test tube and the fluorescence proportional to drug content was measured using a MPF4 fluorescence spectrophotometer (Perkin Elmer, Connecticut, USA). Standards were prepared by adding known amounts of anthracyclines to sodium lauryl sulphate and silver nitrate. The excitation (Ex) and emmission (Em) wavelengths for the spectrofluorimetric analysis of the various anthracyclines were as follows: doxorubicin 490 Ex, 595 Em; iodo-doxorubicin 480 Ex, 590 Em; Ro 31-1215 485 Ex, 565 Em; aclarubicin 450 Ex, 570 Em. 3H-daunorubicin accumulation and efflux Cells were set up in triplicate in 3 cm diameter wells on 6-well plastic tissue culture plates (Sterilin Ltd, Feltham, UK) at a concentration of 8 x 104 well for COR-L12/P and 9 x 104 well for COR-L23/R. The resulting monolayer cultures were used after 4 days of incubation at 370C at which time they had reached the exponential phase of growth. Experiments were carried out using unlabelled daunorubicin at a concentration of 0.4 ig ml-' together with 0.1 sCi mj1 3H-daunorubicin in complete RPMI. The appropriate mixture of labelled and unlabelled compounds was added in a volume of 2ml of fresh medium to the appropriate wells following removal of the growth medium. The dishes containing drug and medium were then incubated at 370C. In efflux experiments, a 60 min loading period was used followed by removal of the medium, rinsing and addition of fresh medium. After the appropriate incubation period, the wells were aspirated dry and the monolayer rinsed twice in 2 ml of ice-cold PBS. The treated monolayers were then lysed with 0.01% sodium dodecyl sulphate in aqueous solution for 20 min. The resulting lysate was mixed by rapid pipetting and 500 l aliquots added to scintillation vials containing 5 ml of Quickzint 401 (Zinsser Analytic, Maidenhead, UK) scintillation fluid. The vials were counted for tritium in a Beckman LS 5000CE liquid scintillation counter for 10 min, and the results were expressed as counts per minute (cpm) per I05 cells following background subtraction. Cell counts were carried out on duplicate wells using trypsin/versene to produce a single-cell suspension. For this the cells were resuspended in 1 ml of medium and 500 IsI aliquots dispensed into 20 ml of Isoton II (Coulter Electronics, Luton, UK). Cell suspensions were then counted using a Coulter ZBI particle counter (Coulter Electronics, Luton, UK).
Energy-dependent anthracycline efflux In these experiments, doxorubicin and daunorubicin were each used at a concentration of 3 sg ml-1. Cells were suspended in glucose-free Eagles' minimal essential medium with the addition of 10 tLM sodium azide. Cell suspensions were incubated for approximately 10min to reach 37°C. At time zero the appropriate compound was added and the initial influx measured at the time points indicated by sampling of the cell suspension followed by washing and processing as for drug accumulation experiments. At 30 min either 20 mM glucose in PBS or the same volume of PBS (100 fil) as solvent control was added and the cell suspensions sampled at various times thereafter. The method is similar to that employed previously by others (Dano, 1973; Inaba & Johnson, 1978) . Table I Figure la . Reduced cellular accumulation was seen for doxorubicin in COR-L23/R, but this was only evident for Drug accumulation in the presence of verapamil 3H-daunorubicin accumulation was unchanged in the COR-L23/P line but was increased by around 60% in the COR-L23/R line (Figure 2) . However, the enhanced DNR accumulation remained no more than 60% of the level seen for the parental COR-L23/P line. Thus, verapamil could only partially correct the accumulation defect seen in COR-L23/R.
Results

Chemosensitivity testing Data in
Efflux of 3H-daunorubicin Following a 60 min loading with 3H-daunorubicin and transfer to drug free medium, drug efflux was significantly enhanced in COR-L23/R compared to the parental line (Figure 3) . At 60 min the cellular drug levels were found to be approximately 55% and 20% of the loading levels for COR-L23/P and COR-L23/R, respectively.
Energy-dependent drug efflux Upon the addition of glucose to cells in drug-containing, glucose-free medium with azide, there was very little effect on cellular doxorubicin content of the COR-L23 parent and resistant lines (Figure 4 ). This suggests no substantial energy-dependent doxorubicin efflux for COR-L23/R. Results in Figure 5 , however, do provide evidence for an energy-dependent efflux of daunorubicin in COR-L23/R. 
Discussion
The finding that cell line COR-L23/R, derived by in vitro exposure to doxorubicin, fails to exhibit P-glycoprotein has provided us with a model to examine in detail the relationship between the expression of this putative multidrug transporter and various other features of the MDR phenotype. The line shows cross-resistance to vincristine, coichicine and etoposide but essentially no cross-resistance to the anthracyclines Ro 31-1215, iodo-doxorubicin, aclarubicin, morpho- linyl doxorubicin and MX2. In this regard, therefore, the resistance profile is closely similar to that seen in our human small cell lung cancer MDR line NCI-H69/LX4 and mouse mammary tumour MDR cell line EMT6/AR1.0, both of which hyperexpress P-glycoprotein (Coley et al., 1989a (Coley et al., , 1990 and submitted for publication).
In contrast to the results of the P-glycoprotein-positive MDR lines, chemosensitisation by verapamil is, however, very modest in COR-L23/R. The highest SRs are seen for vincristine and colchicine. There is also some sensitisation of COR-L23/P. These results are in agreement with previous reports that describe the lack of verapamil-sensitisation seen in non-P-glycoprotein expressing MDR cell lines (Cole et al., 1989; Harker et al., 1989) , and therefore with the concept that P-glycoprotein hyperexpression is a necessary correlate of differential verapamil sensitisation (Croop et al., 1987) .
Hypersensitivity to verapamil alone has been found to be a feature of some, but not all, P-glycoprotein -hyperexpressing MDR cell lines (Reeve et al., 1989b) . Clearly no such hypersensitivity is seen for COR-L23/R.
The anthracycline accumulation profiles in Figure 1 are distinctly different from those obtained for typical MDR cell lines with membrane P-glycoprotein hyperexpression (Fojo et al., 1985; Kessel & Corbett, 1985; Coley et al., 1989b) . Such a pattern of accumulation was, however, previously reported for an doxorubicin-resistant HL-60 cell line which did not express P-glycoprotein (Marsh et al., 1986) . As for the COR-L23/R cell line, accumulation of doxorubicin or daunorubicin was similar in parent and resistant lines over the first half to 1 h, but at later times lower levels were seen in the resistant line. Furthermore an increased ability to efflux daunorubicin is seen in COR-L23/R (Figure 3 ) and this ability is energy-dependent ( Figure 5 ). The energy dependence of doxorubicin efflux is more equivocal (Figure 4) . However, enhanced efflux is generally less for doxorubicin than for daunorubicin, even in P-glycoprotein-positive MDR cell lines (Inaba et al., 1979) . The reason for this is unclear but may possibly be due to different intracellular binding characteristics of the two anthracyclines. The precise mechanism for the delayed activation of this type of energy-dependent efflux process also remains unclear. The data in Table  III demonstrate clearly that the absence of resistance to iodo-doxorubicin and aclarubicin seen in COR-L23/R is associated with improved accumulation over that seen for doxorubicin.
From the results described herein, COR-L23/R is clearly another example of atypical MDR. Following the description of the HL-60 line (see above) (Marsh et al., 1986 ) the next report of an MDR cell line without P-glycoprotein expression described an MDR variant of the CEM human lymphoblastoid leukaemia cell line selected for resistance to teniposide (Danks et al., 1987) . The cell line showed cross-resistance to many natural product cytotoxic agents including etoposide, but retained sensitivity to vinca alkaloids. However, the ability to accumulate etoposide was unaltered from that of the parental line. The resistance seen in this cell line was attributed to a decrease in the catalytic activity of, and DNA cleavage by, the nuclear enzyme topoisomerase II (Danks et al., 1987 (Danks et al., , 1988 . Such a mechanism has also been invoked to explain atypical MDR in a small cell lung cancer line GLC4/ ADR (Zijistra et al., 1987) . This line, however, was not resistant to colchicine or actinomycin D but did show defective doxorubicin accumulation. Atypical MDR in a resistant leukaemia cell line derived from a patient with refractory disease following chemotherapy has also been reported (Haber et al., 1990) . The line showed vincristine resistance and no P-glycoprotein hyperexpression as determined using the C-219 antibody. However, no pre-and post-treatment comparisons were made and the authors used the leukaemic CCRF-CEM cell line as the drug sensitive reference. Thus the report, whilst interesting, should be regarded with some caution. COR-L23/R also shares some properties with a doxorubicin-resistant fibrosarcoma line HT 1080/DR4 (Slovak et al., 1988) in that P-glycoprotein expression was absent despite changes in drug accumulation and cross-resistance to cytotoxics including vincristine. To date therefore, no convincing explanation is available for the mechanistic basis of cell lines such as COR-L23/R which show resistance to the full spectrum of MDR drug, and also exhibit a drug accumulation defect, yet do not hyperexpress P-glycoprotein.
A recent report (Marquardt et al., 1990) has described an Mr 190,000 membrane-associated protein in an doxorubicinresistant variant of HL-60 cells with no P-glycoprotein. Close structural homology to the ATP binding site on P-glycoprotein has been demonstrated using a panel of antibodies against specific sequences of P-glycoprotein and hence P-190 is proposed to be an alternative drug efflux protein. However, no reactivity with the P-glycoprotein C-219 antibody (Kartner et al., 1985) was seen, as was the case for COR-L23/R (Reeve et al., 1990) . In view of a demonstrable capacity to efflux daunorubicin, COR-L23/R may too possess an alternative multidrug transporter.
The very high levels of drug resistance seen in many Pglycoprotein expressing cell lines may not of course be relevant to drug resistance as seen in the clinic. However, for tumour types which have been shown in patients to express P-glycoprotein, the mRNA levels can be higher than those seen in a human cell line which is 4-and 6-fold more resistant to doxorubicin and vinblastine respectively than the parent line . A comprehensive study of lung cancer cell lines derived from untreated or previously treated small cell lung cancer patients (Carmichael et al., 1985) showed mean relative resistance of the latter to doxorubicin, vincristine and etoposide of 4.8, 2.6 and 9.4-fold respectively. It was subsequently shown that the lines from the previously treated patients do not show increased Pglycoprotein expression as compared to the untreated lines (Lai et al., 1989) . In the case of lung cancer, therefore, the very high levels of resistance with P-glycoprotein hyperexpression seen in MDR line NCI-H69/LX4 may not be a good model for clinical resistance. The lower levels of resistance without P-glycoprotein hyperexpression seen in H69/AR (Mirski et al., 1987 ) and now in COR-L23/R may be more relevant.
With regard to therapeutic strategies, our results indicate that the use of verapamil and possibly other resistance modifiers may not be effective where resistance is not associated with P-glycoprotein hyperexpression. On the other hand, the strategy which we have described (Twentyman et al., 1986a; Scott et al., 1986; Coley et al., 1989a Coley et al., , 1990 ) of using anthracycline analogues which do not show reduced accumulation in MDR cells is effective both in the presence and absence of P-glycoprotein. It therefore may have more general applicability. The mechanisms by which the analogues maintain accumulation in COR-L23/R is unclear, but may involve avoidance of an alternative energy-dependent multidrug transporter.
